Objective
to compare the safety and efficacy of biodegradable-polymer sirolimus-eluting stent (BP-SES) with durable-polymer zotarolimus-eluting stent (DP-ZES) in high-bleeding risk patients receiving one-month DAPT and thereafter single antiplatelet therapy
Study
open-label, randomised trial (non-inferiority margin 4.1%)
Population
patients with acute or chronic coronary syndrome and high bleeding risk
Endpoints
composite of cardiac death, MI or stent thrombosis at 1 year
Conclusion
amongst patients with high bleeding risk undergoing PCI with 1-month DAPT BP-SES is non-inferior to DP-ZES
Valgimigli et al. Circulation 2023:online August 25
